Quantum-Si Incorporated ( (QSI) ) has released its Q4 earnings. Here is a breakdown of the information Quantum-Si Incorporated presented to its investors.
Quantum-Si Incorporated, known as The Protein Sequencing Company™, is a leader in the proteomics industry, focusing on advancing research, drug discovery, and diagnostics through its innovative protein sequencing technology.
In its latest earnings report, Quantum-Si announced a significant milestone by achieving its first quarterly revenue exceeding $1 million, with a total of $1.2 million for the fourth quarter of 2024 and $3.1 million for the full year, marking a 183% year-over-year growth. The company also successfully raised $86 million in capital, extending its cash runway into the second half of 2027.
Key highlights from the report include the launch of the Platinum Pro instrument and new kits, which are expected to drive future growth. The company maintained a gross margin of 51% for the fourth quarter and 52% for the full year, despite variable margins due to the early stages of commercialization. Operating expenses were optimized, remaining relatively flat year-over-year, while a restructuring program was implemented to streamline resources.
Despite reporting a net loss of $33.1 million for the fourth quarter, Quantum-Si remains optimistic about 2025, with expectations of significant revenue growth driven by new product launches and strategic partnerships. The company’s strong cash position and strategic initiatives are anticipated to enhance customer adoption and market presence.
Looking forward, Quantum-Si’s management is focused on commercial execution and expanding its distribution network, with several product launches and scientific data releases planned for 2025. The company aims to capitalize on its innovative technology to achieve greater results in the coming year.